抗酒石酸酸性磷酸酶 5b 同工酶在评估骨质疏松症治疗反应中的应用有限。
Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis.
机构信息
Metabolism Laboratory, St. Vincent's University Hospital, Dublin, Ireland,
出版信息
Ir J Med Sci. 2014 Mar;183(1):47-52. doi: 10.1007/s11845-013-0970-6. Epub 2013 Jun 5.
BACKGROUND
Tartrate-resistant acid phosphatase isoform 5b (TRACP5b) is a serum bone resorption marker. Our aim was to investigate its utility in monitoring metabolic bone disease.
METHODS
Serum TRACP5b, C-terminal cross-linking telopeptide of type I collagen, urine N-terminal cross-linking telopeptide of type I collagen and free deoxypyridinoline were measured pre- and post-treatment with a parathyroid hormone analogue [PTH (1-34)] (n = 14) or a bisphosphonate (N-BP) (n = 8). TRACP5b, bone alkaline phosphatase (bone ALP), 25-hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) were measured in 100 osteoporosis patients on prolonged bisphosphonate therapy.
RESULTS
Changes in TRACP5b were smaller in magnitude but mimicked those of other bone resorption markers. Absolute changes in TRACP5b and the other resorption markers correlated significantly (p < 0.001). In patients on long-term bisphosphonates, TRACP5b and bone ALP levels were not suppressed. Vitamin D status was consistent with the level of supplementation.
CONCLUSION
TRACP5b has limited utility as a single marker of metabolic bone disease treatment.
背景
抗酒石酸酸性磷酸酶 5b 同工酶（TRACP5b）是血清骨吸收标志物。我们的目的是研究其在代谢性骨病监测中的应用。
方法
我们对接受甲状旁腺激素类似物（PTH（1-34））（n=14）或双膦酸盐（N-BP）（n=8）治疗的 14 例患者治疗前后的血清 TRACP5b、Ⅰ型胶原 C 端交联肽、Ⅰ型胶原 N 端交联肽和游离脱氧吡啶啉进行了检测。我们还对 100 例长期接受双膦酸盐治疗的骨质疏松症患者的 TRACP5b、骨碱性磷酸酶（bone ALP）、25-羟维生素 D（25OHD）和甲状旁腺激素（PTH）进行了检测。
结果
TRACP5b 的变化幅度较小，但与其他骨吸收标志物的变化相似。TRACP5b 和其他吸收标志物的绝对变化显著相关（p<0.001）。在长期接受双膦酸盐治疗的患者中，TRACP5b 和骨 ALP 水平未被抑制。维生素 D 状态与补充水平一致。
结论
TRACP5b 作为代谢性骨病治疗的单一标志物的应用价值有限。
Zotero 插件